<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137755">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01761981</url>
  </required_header>
  <id_info>
    <org_study_id>1900</org_study_id>
    <nct_id>NCT01761981</nct_id>
  </id_info>
  <brief_title>Institutional Registry of Haemorrhagic Hereditary Telangiectasia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Italiano de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Italiano de Buenos Aires</source>
  <oversight_info>
    <authority>Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica: Argentina</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to create an institutional and population-based registry of
      Haemorrhagic Hereditary Telangiectasia with a prospective survey based on epidemiological
      data, risk factors, diagnosis, prognosis, treatment, monitoring and survival.

      This study will also describe the occurrence of Haemorrhagic Hereditary Telangiectasia  in
      the population of HIBA in the Central Hospital, as well as the characteristics of clinical
      presentation and evolution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Haemorrhagic Hereditary Telangiectasia is a uncommon autosomic hereditary disorder
      caracterizad for recurrent epistaxis,cutaneomucous telangiectasias and arteriovenous
      malformations in diferent organs; brain, lung, liver and gastrointestinal are more often
      afected . Afect one in 5000-8000 individual in worldwide. HHT may produce important
      morbidity like brain absces, stroke, hemoptisis and cronic ferropenic anemia.

      Molecular mechanism of this disorder are complex and still no fully dilucidated. The genes
      mutated in HHT encode endothelial cell-expressed proteins that mediate signalling by the
      transforming growth factor (TGF)b superfamily. Endoglin (HHT type I) and ACVRL-1 (HHT type
      2)  mutations are responsible in more than 80% of the individuals. Mutation of SMAD 4
      protein (MADH4)cause HHT in association with juvenile polyposis. HHT may associated with
      primary pulmonary hypertension en more rare cases.

      There arent HHT register in Argentina and Latinamerican population. This registry may gader
      valious information in order to generate a better diagnosis and treatment of our population
      and others.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>morbidity</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Control visit every three month</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Haemorrhagic Hereditary Telangiectasia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Haemorrhagic Hereditary Telangiectasia
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with HHT defined.

          2. Followed in Unidad HHT of Hospital Italiano de Buenos Aires.

        Exclusion Criteria:

        1. Denied to participated in the registry or inform consent process.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcelo Martin Serra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HHT Center of Excelence Hospital Italiano de Buenos Aires</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcelo Martin Serra, MD</last_name>
    <phone>+541149590200</phone>
    <phone_ext>4419</phone_ext>
    <email>marcelo.serra@hospitalitaliano.org.ar</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diego Hernan Giunta, MD</last_name>
    <phone>+541149590200</phone>
    <phone_ext>4419</phone_ext>
    <email>diego.giunta@hospitalitaliano.org.ar</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1081</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelo Martin Serra, MD</last_name>
      <phone>+541149590200</phone>
      <phone_ext>4419</phone_ext>
      <email>marcelo.serra@hospitalitaliano.org.ar</email>
    </contact>
    <contact_backup>
      <last_name>Diego Hernan Giunta, MD</last_name>
      <phone>+541149590200</phone>
      <phone_ext>4419</phone_ext>
      <email>diego.giunta@hospitalitaliano.org.ar</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <link>
    <url>http://www.hospitalitaliano.org.ar/hht</url>
    <description>Web site to health workers and patients comunity about Haemorrhagic Hereditary Telangiectasia</description>
  </link>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 3, 2013</lastchanged_date>
  <firstreceived_date>January 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Italiano de Buenos Aires</investigator_affiliation>
    <investigator_full_name>Diego Giunta</investigator_full_name>
    <investigator_title>Marcelo Martin Serra</investigator_title>
  </responsible_party>
  <keyword>Haemorrhagic Hereditary Telangiectasia</keyword>
  <keyword>Rendu Osler Weber Syndrome</keyword>
  <keyword>Osler Weber Rendu Syndrome</keyword>
  <keyword>HHT</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Telangiectasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
